Implementation of microsatellite instability testing for the assessment of solid tumors in clinical practice.

ABSTRACT:

Background

In Japan, microsatellite instability (MSI) testing for solid tumors was introduced in clinical practice in December 2018. Although immune checkpoint inhibitors (ICIs) are established standards of care for patients with MSI-high tumors, the status of implementing MSI testing in clinical practice remains unclear.

Methods

We retrospectively reviewed the medical records of patients with solid tumors who underwent MSI testing between January 2019 and December 2020 at our institution.

Results

In total, 1,052 MSI tests were performed in 1,047 patients. Regardless of specimen volume and condition, the MSI status was successfully determined in 1,041 (99.0%) tests, encompassing 27 tumor types (microsatellite stable [MSS] or MSI-low: n = 991 [95.2%] and MSI-high: n = 

SUBMITTER: Nakayama I 

PROVIDER: S-EPMC10134335 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature